Pancreastatin: A novel biomarker for diabetes
Principal Investigator
Prof. Nitish R. Mahapatra
Objective
- To analyze plasma pancreastatin levels and relevant clinical parameters., To determine the pancreastatin genotypes in the subjects.
Description
- The prevalence of type 2 diabetes has increased to an alarming level in recent years., Currently about 10% of the adult population, that is approximately 500 million people around the world, have this disease condition., We have recently discovered that plasma level of a physiological peptide, called pancreastatin is elevated in type 2 diabetes patients., We have also identified a genetic variation in pancreastatin in 15% of Indian populations. These people are at a significantly higher risk of cardiovascular and metabolic diseases.
Impact
- The findings from these studies may establish that elevated plasma pancreastatin (PST) level is an intermediate phenotype for type 2 diabetes., Establishment of PST levels and Gly297Ser variant as novel biomarkers., Development of an early biomarker for better clinical management of diabetes., Kit for speedy detection of PST levels.
Budget in Lakhs
50.00
Duration
3 Years